Dermata Therapeutics, Inc. DRMA 深 滬
等待開盤 11-04 09:30:00 美东时间
0.8487
+0.095
+12.59%
華盛通- 最 高0.9094
- 今 開0.7565
- 成交量 22.59万股
- 最 低 0.7201
- 昨 收 0.7538
- 總市值 420.55万
- 52周最高 4.66
- 市盈率 靜 --
- 換手率 4.56%
- 52周最低 0.6032
- 委 比 33.33%
- 總股本 495.52万
- 歷史最高 16680.00
- 量 比 1.90
- 振 幅 25.11%
- 歷史最低 0.6032
- 每 手 1
- 風險率 0.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Dermata Therapeutics Stock Gaining Thursday?
On Thursday, Dermata Therapeutics Inc. (NASDAQ:DRMA) announced positive topline results from a cosmetic clinical study evaluating its recently launched skin renewal treatment, Tome Foundational Treatment. Following the announcement, the stock jumped nearly 34%. Study Findings Support Efficacy The op...
10-16 01:29
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly ...
10-15 20:10
Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?
Dermata Therapeutics Inc. (NASDAQ:DRMA) shares jumped 27.78% to $1.38 in the pre-market session on Wednesday after the San Diego-based company reported second-quarter results for the period ended Jun. 30 on Tuesday. Earnings per share came in at -$0.74, missing the analyst estimate of -$0.55 by 34.5...
08-12 17:20
Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 89.33 percent increase over losses of $(4.50) per share
05-14 04:48
Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia, and Japan covering
04-02 20:38
Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.54) by 1.3 percent. This is a 83.48 percent increase over losses of $(9.20) per share
03-27 05:18
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday...
03-20 20:05
Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS"
https://patentcenter.uspto.gov/applications/17546001/ifw/docs
03-20 04:00
Why Comfort Systems Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Comfort Systems USA Inc (NYSE:FIX) rose sharply in pre-market trading...
02-20 18:16
The Australian Patent Office Grants Dermata Therapeutics' Patent Application for Its Spongilla Technology Combination as a Method for Treating Acne
The Company's innovative acne kit represents a new approach to acne treatment by targeting the underlying acne-causing mechanisms with enhanced precision and effectiveness. Unlike traditional therapies, the Company
01-20 21:09
